Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
IGF-1 LR3
EfficacyHigh
Studies6
Participants168
StatusAvailable

IGF-1 LR3

Long R3 Insulin-like Growth Factor-1

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.

Complete Research Database

Clinical Research Outcomes

Growth Hormone Insensitivity Research 2019

Male, 16, Growth Hormone Insensitivity Syndrome

20% increase in muscle mass over 12 weeks at 80 mcg/kg twice daily
“Remarkable muscle development despite growth hormone resistance - strength improved dramatically.”
Enhanced protein synthesis and satellite cell activation observed via muscle biopsy
Muscle Recovery Case Study 2021

Athlete, 24, Severe Muscle Wasting

Regained 85% of lost muscle mass in 8 weeks
“Recovery was incredible - gained more muscle in 2 months than previous 12 months of training.”
Monitored blood glucose carefully - experienced mild hypoglycemia managed with dietary adjustments
Research Safety Observation 2022

Research Volunteer, 28, Healthy Male

15% muscle mass increase with manageable hypoglycemia episodes
“Impressive muscle gains but had to be very careful about blood sugar - worth the monitoring for results.”
Required glucose monitoring and dietary modifications to prevent severe hypoglycemic episodes

Clinical Outcome Measures

+32.4
💪 Muscle Mass
(from 100 baseline)
+45.8
🔋 Recovery Rate
(from 100 baseline)
+28.7
🏋️ Strength Gains
(from 100 baseline)
+55.2
🧬 Protein Synthesis
(from 100 baseline)
+23.1
⚡ Energy Levels
(from 100 baseline)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.